

Category: Study conduct

Title: Contact and communication with sponsor

SOP No.: D 21/05

Date first effective: 01 Jan 2023

Review date: 31 Dec 2023

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Category: Study conduct

Title: Contact and communication with sponsor

SOP No.: D 21/05

Total pages: 05

Date first effective: 01 Jan 2023

Next Review date: 31 Dec 2023

Version: 05

Author: Dr. Dhruve Soni
DM Resident

Signature with date

Dr. Mahesh N. Belhekar
31/DEC/2022

Reviewer:

Dr. Mahesh N. Belhekar
Associate Professor
Department of Clinical Pharmacology
New MS Building, First Floor,
Seth GS Medical College and KEM Hospital
Acharya Donde Marg, Parel,
Mumbai - 400 012, India

Signature with date

Dr. Nithya Gogtay
31/DEC/2022

Approved by:

Dr. Nithya Gogtay
Professor and Head

Signature with date

Dr. Nithya Gogtay
31/12/22

Dr. Nithya Gogtay

Professor & Head

Department of Clinical Pharmacology

1st Floor, MS Building,

Seth GS Medical College & KEM Hospital

Parel, Mumbai - 400 012.

Category: Study conduct

Title: Contact and communication with sponsor

SOP No.: D 21/05

Date first effective: 01 Jan 2023

Review date: 31 Dec 2023

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Table of Contents

No.	Contents	Page No.
1	Purpose	3
2	Scope	3
3	Responsibility	3
4	Applicable rules, regulations and guidelines	3
5	Detailed instructions	4

Category: Study conduct

Title: Contact and communication with sponsor

SOP No.: D 21/05

Date first effective: 01 Jan 2023

Review date: 31 Dec 2023

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

1. Purpose

The purpose of this SOP is to instruct the study team in communication with the sponsor.

2. Scope

This SOP applies to all forms of communications of the site (email, telephone, fax etc.) with the sponsor.

3. Responsibilities

Principal investigator (PI), Co – investigator (Co-I), study coordinator or the delegated study team members will be responsible for communication with the sponsor.

4. Applicable rules, regulations and guidelines

- New Drugs and Clinical Trials Rules, 2019
- Ethical Guidelines for Biomedical and Health Research involving Human Participants, ICMR 2017.
- ICH E6(R3) EWG Draft Guidelines dated 19th April, 2021.

5. Reference to other applicable SOPs

- SOP No. D 17/05: Continued interaction with the Institutional Ethics Committees
- SOP No. D 15/05: Serious Adverse Event (AE) Monitoring, Recording and Reporting
- SOP NO. D 2A/05: Preparing the site team for a clinical study sponsored by Pharmaceutical company

6. Detailed Instructions

1. The PI will be responsible for the initial communication with the sponsor.
2. PI or Co-I inform the sponsor about study team and keeps the sponsor updated on changes in the study team in the course of the trial.
3. The PI or a Co-I delegate routine communication to the study coordinator on updates, document submissions and receipt.

Category: Study conduct

Title: Contact and communication with sponsor

SOP No.: D 21/05

Date first effective: 01 Jan 2023

Review date: 31 Dec 2023

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

4. Communications pertaining to financial, technical and regulatory aspects should be done only by the PI or Co-I unless otherwise instructed.
5. If the sponsor/s collaborate with Contract Research organization (CRO) for any study, majority of the communication will be done with the CRO and the specific aspects with the sponsor/s and CRO which has to be decided a priori.
6. Any telephonic conversations should be immediately transcribed to the emails and will be communicated to all the members of the study team and sponsor/s and CRO (if relevant)
7. All the emails should be acknowledged by the study team members.
8. All the study members should be kept in the email loop to keep them updated.
9. All the study team members should be objective, precise, polite and professional in all communication with the sponsor/s.
10. Etiquette should always be maintained in the communication. e.g. Doctor XYZ should be addressed as Dear Dr. XYZ.
11. The study team members will put a "Vacation reply" mentioning the dates and duration of absence, date of resumption and backup person's name, email and mobile number during the absence.
12. All important communications should be documented in printed form and kept in trial master file.
13. Sponsor should be updated at specified interval [depending on the SOP of the sponsor] about the progress of the trial through formal email
14. During all the phases of the trial, scanned documents of relevant EC communications should be conveyed through formal email.

Category: Study conduct

Title: Contact and communication with sponsor

SOP No.: D 21/05

Date first effective: 01 Jan 2023

Review date: 31 Dec 2023

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Reviewer:

Dr. Mahesh Belhekar
Associate Professor

Signature with date

Bel
31/Dec/2022
Dr. Mahesh N. Belhekar
Associate Professor
Department of Clinical Pharmacology
New MS Building, First Floor,
Seth GS Medical College and KEM Hospital
Acharya Donde Marg, Parel,
Mumbai - 400 012. India

Approved by:

Dr. Nithya Gogtay
Professor and Head

Signature with date

N
31.12.22

Dr. Nithya Gogtay

Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building,
Seth GS Medical College & KEM Hospital,
Parel, Mumbai - 400 012.